Loader

Pathways

PathWhiz ID Pathway Meta Data

PW128107

Pw128107 View Pathway
drug action

Selexipag Action Pathway

Homo sapiens
Selexipag is a non-prostanoid prostacyclin receptor agonist, also known as Uptravi typically used to treat pulmonary arterial hypertension. Selexipag is a selective prostacyclin receptor agonist, it is administered orally and is metabolized by carboylesterase1 into its active metabolite (ACT-333679). The metabolite has a high selectivity for prostacyclin receptor that activates it and subsequent G coupled protein, Gs, that increases cAMP levels. Increased cAMP levels leads to inhibited platelet aggregation and activation.

PW146368

Pw146368 View Pathway
drug action

Selexipag Drug Metabolism Action Pathway

Homo sapiens

PW132448

Pw132448 View Pathway
metabolic

Selinexor Drug Metabolism

Homo sapiens
Selinexor is a drug that is not metabolized by the human body as determined by current research and biotransformer analysis. Selinexor passes through the liver and is then excreted from the body mainly through the kidney.

PW146472

Pw146472 View Pathway
drug action

Selinexor Drug Metabolism Action Pathway

Homo sapiens

PW146936

Pw146936 View Pathway
drug action

Selpercatinib Drug Metabolism Action Pathway

Homo sapiens

PW146426

Pw146426 View Pathway
drug action

Selumetinib Drug Metabolism Action Pathway

Homo sapiens

PW146701

Pw146701 View Pathway
drug action

Semaglutide Drug Metabolism Action Pathway

Homo sapiens

PW121812

Pw121812 View Pathway
disease

Sepiapterin Reductase Deficiency

Mus musculus
Sepiapterin reductase deficiency results from a metabolic disorder; namely, the underproduction of Sepiapterin. The cause of this underproduction is an autosomal recessive genetic mutation in the SPR gene. This gene is responsible for Sepiapterin production, and naturally, when the gene malfunctions the production of this metabolite is altered leading to a range of effects on the body. In this case, some symptoms of Sepiapterin Deficiency are: motor and speech delay, axial hypotonia, dystonia, weakenss microcephaly, dysarthria, autonomic dysfunction, oculogyric crises, drowsiness, among others.

PW000467

Pw000467 View Pathway
disease

Sepiapterin Reductase Deficiency

Homo sapiens
Sepiapterin reductase deficiency results from a metabolic disorder; namely, the underproduction of Sepiapterin. The cause of this underproduction is an autosomal recessive genetic mutation in the SPR gene. This gene is responsible for Sepiapterin production, and naturally, when the gene malfunctions the production of this metabolite is altered leading to a range of effects on the body. In this case, some symptoms of Sepiapterin Deficiency are: motor and speech delay, axial hypotonia, dystonia, weakenss microcephaly, dysarthria, autonomic dysfunction, oculogyric crises, drowsiness, among others.

PW122037

Pw122037 View Pathway
disease

Sepiapterin Reductase Deficiency

Rattus norvegicus
Sepiapterin reductase deficiency results from a metabolic disorder; namely, the underproduction of Sepiapterin. The cause of this underproduction is an autosomal recessive genetic mutation in the SPR gene. This gene is responsible for Sepiapterin production, and naturally, when the gene malfunctions the production of this metabolite is altered leading to a range of effects on the body. In this case, some symptoms of Sepiapterin Deficiency are: motor and speech delay, axial hypotonia, dystonia, weakenss microcephaly, dysarthria, autonomic dysfunction, oculogyric crises, drowsiness, among others.